Arbutus Biopharma Co. (NASDAQ:ABUS) Short Interest Update

Arbutus Biopharma Co. (NASDAQ:ABUSGet Free Report) was the target of a large increase in short interest in June. As of June 15th, there was short interest totalling 5,370,000 shares, an increase of 6.8% from the May 31st total of 5,030,000 shares. Based on an average daily trading volume, of 1,270,000 shares, the short-interest ratio is currently 4.2 days.

Analyst Upgrades and Downgrades

Several brokerages have issued reports on ABUS. HC Wainwright reaffirmed a “buy” rating and set a $5.00 price objective on shares of Arbutus Biopharma in a report on Thursday, June 6th. JMP Securities reaffirmed a “market outperform” rating and set a $4.00 price target on shares of Arbutus Biopharma in a research report on Thursday, April 4th. Finally, Chardan Capital reissued a “buy” rating and issued a $4.00 price objective on shares of Arbutus Biopharma in a report on Wednesday, June 5th.

Check Out Our Latest Research Report on ABUS

Hedge Funds Weigh In On Arbutus Biopharma

Several institutional investors have recently bought and sold shares of ABUS. Walleye Trading LLC acquired a new position in shares of Arbutus Biopharma during the 1st quarter worth $36,000. China Universal Asset Management Co. Ltd. increased its holdings in Arbutus Biopharma by 351.6% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 19,400 shares of the biopharmaceutical company’s stock valued at $49,000 after buying an additional 15,104 shares in the last quarter. PFG Investments LLC acquired a new stake in shares of Arbutus Biopharma during the 1st quarter valued at approximately $50,000. Premier Path Wealth Partners LLC purchased a new stake in shares of Arbutus Biopharma during the 4th quarter worth approximately $56,000. Finally, Price T Rowe Associates Inc. MD grew its holdings in shares of Arbutus Biopharma by 22.4% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 36,388 shares of the biopharmaceutical company’s stock worth $94,000 after acquiring an additional 6,649 shares during the period. 43.79% of the stock is owned by institutional investors and hedge funds.

Arbutus Biopharma Stock Up 1.0 %

NASDAQ ABUS opened at $3.16 on Thursday. The firm has a market cap of $596.36 million, a P/E ratio of -7.18 and a beta of 1.96. Arbutus Biopharma has a 52-week low of $1.69 and a 52-week high of $3.64. The business’s 50-day moving average price is $3.07 and its 200 day moving average price is $2.77.

Arbutus Biopharma (NASDAQ:ABUSGet Free Report) last announced its earnings results on Thursday, May 2nd. The biopharmaceutical company reported ($0.10) earnings per share for the quarter, meeting the consensus estimate of ($0.10). Arbutus Biopharma had a negative return on equity of 62.68% and a negative net margin of 572.81%. The company had revenue of $1.53 million for the quarter, compared to the consensus estimate of $2.16 million. As a group, analysts anticipate that Arbutus Biopharma will post -0.39 earnings per share for the current year.

About Arbutus Biopharma

(Get Free Report)

Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection in the United States. Its HBV product pipeline consists of imdusiran (AB-729), a proprietary subcutaneously-delivered RNAi therapeutic product candidate that suppresses all HBV antigens, including HBsAg expression.

Featured Articles

Receive News & Ratings for Arbutus Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arbutus Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.